JNJ - Emergent BioSolutions Will Manufacture AstraZeneca's COVID-19 Vaccine Candidate
Small-cap Emergent BioSolutions (NYSE: EBS) has landed another contract to manufacture a possible COVID-19 vaccine, this time with European pharmaceutical giant AstraZeneca. Of course, the contract, said to be worth as much as $87 million, hinges on whether AstraZeneca's vaccine gets approved by the Food and Drug Administration for human use.
Emergent is a contract development and manufacturing organization that has relationships with many biotech and pharmaceutical companies (not to mention the federal government). Back in April, it inked a similar deal with Johnson & Johnson worth up to $135 million.
Image source: Getty Images